title: Comparison of roflumilast, an oral anti-inflammatory, with beclomethasone dipropionate in the treatment of persistent asthma.
abstract: BACKGROUND
  Roflumilast is an oral, once-daily phosphodiesterase 4 inhibitor with anti-inflammatory activity in development for the treatment of asthma. Roflumilast was compared with inhaled beclomethasone dipropionate (BDP) in patients with asthma.
  
  
  METHODS
  In a double blind, double-dummy, randomized, noninferiority study, 499 patients (forced expiratory volume in 1 s [FEV1] = 50-85% predicted) received roflumilast 500 microg once daily or BDP 200 microg twice daily (400 microg/day) for 12 weeks. Lung function and adverse events were monitored.
  
  
  RESULTS
  Roflumilast and BDP significantly improved FEV1 by 12% (270 +/- 30 ml) and 14% (320 +/- 30 ml), respectively (P < 0.0001 vs baseline). Roflumilast and BDP also significantly improved forced vital capacity (FVC) (P < 0.0001 vs baseline). There were no significant differences between roflumilast and BDP with regard to improvement in FEV1 and FVC. Roflumilast and BDP showed small improvements in median asthma symptom scores (-0.82 and -1.00, respectively) and reduced rescue medication use (-1.00 and -1.15 median puffs/day, respectively; P < 0.0001 vs baseline). These small differences between roflumilast and BDP were not considered clinically relevant. Both agents were well tolerated.
  
  
  CONCLUSIONS
  Once daily, oral roflumilast 500 microg was comparable with inhaled twice-daily BDP (400 microg/day) in improving pulmonary function and asthma symptoms, and reducing rescue medication use in patients with asthma.
authors.affiliation: Hôpital Arnaud de Villeneuve, Montpellier, France.
authors.forename: J
authors.initials: J
authors.lastname: Bousquet
authors.forename: M
authors.initials: M
authors.lastname: Aubier
authors.forename: J
authors.initials: J
authors.lastname: Sastre
authors.forename: J L
authors.initials: JL
authors.lastname: Izquierdo
authors.forename: L M
authors.initials: LM
authors.lastname: Adler
authors.forename: P
authors.initials: P
authors.lastname: Hofbauer
authors.forename: K-D
authors.initials: KD
authors.lastname: Rost
authors.forename: U
authors.initials: U
authors.lastname: Harnest
authors.forename: B
authors.initials: B
authors.lastname: Kroemer
authors.forename: A
authors.initials: A
authors.lastname: Albrecht
authors.forename: D
authors.initials: D
authors.lastname: Bredenbröker
mesh_terms: D000280:Administration, Inhalation; D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000368:Aged; D000631:Aminopyridines / Q000008:administration & dosage*; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage*; D001249:Asthma / Q000175:diagnosis / Q000188:drug therapy*; D001507:Beclomethasone / Q000008:administration & dosage*; D001549:Benzamides / Q000008:administration & dosage*; D002648:Child; D003521:Cyclopropanes / Q000008:administration & dosage; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D005541:Forced Expiratory Volume; D006801:Humans; D008297:Male; D008875:Middle Aged; D010726:Phosphodiesterase Inhibitors / Q000008:administration & dosage*; D011336:Probability; D012129:Respiratory Function Tests; D018570:Risk Assessment; D012720:Severity of Illness Index; D018709:Statistics, Nonparametric; D016896:Treatment Outcome
chemical_list: D000631:Aminopyridines; D000893:Anti-Inflammatory Agents; D001549:Benzamides; D003521:Cyclopropanes; D010726:Phosphodiesterase Inhibitors; C424423:Roflumilast; D001507:Beclomethasone